Quetiapine is the antipsychotic with the broadest bipolar disorder approval, and that fact is what gives it a distinct place in this stage. FDA-approved for acute mania, bipolar depression, and maintenance — three phases of one disease, three approvals for one agent. Few single drugs cover the bipolar spectrum this completely.
- Class
- Second-generation antipsychotic (used as mood stabilizer)
- Mechanism
- Multi-receptor: D2 antagonism, 5-HT2A antagonism, H1 antagonism, alpha-1 antagonism, modest NET inhibition (active metabolite norquetiapine)
- Typical dose
- Bipolar mania 400-800 mg/day; bipolar depression 300 mg/day; maintenance variable
- Half-life
- ~6 hours (XR formulation extends duration)
- FDA indications
- Bipolar I (acute mania, bipolar depression, maintenance), schizophrenia, MDD augmentation
- Key adverse effects
- Sedation (prominent at low and moderate doses), weight gain, metabolic effects (lipids, glucose), orthostasis, dry mouth, EPS (rare)
Unique among antipsychotics: FDA approved for both acute mania and bipolar depression. The bipolar depression efficacy is unusual among mood-stabilizing agents. Sedation can be therapeutic (insomnia) but limits daytime tolerability.
The mechanism is multi-receptor — D2 antagonism, 5-HT2A antagonism, H1 antagonism (sedation), alpha-1 antagonism (orthostasis), and 5-HT1A partial agonism. The active metabolite, norquetiapine, adds NET inhibition — and that's almost certainly what gives quetiapine its bipolar depression effect, distinguishing it from antipsychotics that don't help mood downward.
Quetiapine in bipolar disorder is the clearest clinical example of dose-dependent receptor recruitment — different receptors engage as the dose climbs, producing different therapeutic effects.
Mechanism note: Quetiapine recruits receptors sequentially by dose — antihistamine low, antidepressant mid, antipsychotic high. The patient on 50mg for sleep is getting an antihistamine, not a mood stabilizer.
For acute mania, doses of 400-800 milligrams produce reliable antimanic effect within a week. For bipolar depression, 300 milligrams is the typical target. For maintenance, the dose varies by patient stability.
The trade-off is the metabolic profile. Quetiapine causes substantial weight gain — often 5-15 pounds over the first months — and meaningful lipid and glucose effects over time. Monitor weight every visit, lipids and A1c annually. The patient already prediabetic or obese should be considered carefully before quetiapine; the patient stable on quetiapine who develops new metabolic syndrome may need a different mood stabilizer.
Sedation is the other constraint. Quetiapine is one of the more sedating antipsychotics, especially in the low-to-moderate dose range. The widespread off-label use of low-dose quetiapine (25-100mg) for sleep is partly because of this sedating effect — though that use is itself controversial given the metabolic profile.
For the bipolar patient who needs a single agent that covers all three phases and can tolerate the metabolic burden, quetiapine is a reasonable choice. For the patient with metabolic risk, lurasidone or cariprazine often serves the same coverage with much less metabolic cost.
- Cost
- Generic: ~$15-50/month. Brand Seroquel rare.
- Generic status
- Generic since 2012.
- Formulary typical
- Tier 1-2 generic. PA rarely needed.
- Access friction
- Cheap and accessible — easy to prescribe, easy to over-prescribe for sleep. Off-label sleep use is widespread but contentious given metabolic burden.
Prescriber tip: Document metabolic monitoring schedule (weight, lipids, A1c). For low-dose sleep use, weigh the antipsychotic-class concerns against trazodone or other alternatives.